Back to Search Start Over

Switching the Chemoselectivity in the Preparation of [ 18 F]FNA- N -CooP, a Free Thiol-Containing Peptide for Targeted Positron Emission Tomography Imaging of Fatty Acid Binding Protein 3.

Authors :
Dillemuth P
Lövdahl P
Karskela T
Ayo A
Ponkamo J
Liljenbäck H
Paunonen S
Kunnas J
Rajander J
Tynninen O
Rosenholm JM
Roivainen A
Laakkonen P
Airaksinen AJ
Li XG
Source :
Molecular pharmaceutics [Mol Pharm] 2024 Aug 05; Vol. 21 (8), pp. 4147-4156. Date of Electronic Publication: 2024 Jul 15.
Publication Year :
2024

Abstract

Fatty acid binding protein 3 (FABP3) is expressed both in tumor cells and in the tumor vasculature, making it a potential target for medical imaging and therapy. In this study, we aimed to radiolabel a CooP peptide with a free amino and thiol group, and evaluate the radiolabeled product [ <superscript>18</superscript> F]FNA- N -CooP for imaging FABP3 expression in breast cancer brain metastases by positron emission tomography. [ <superscript>18</superscript> F]FNA- N -CooP was prepared by highly chemoselective N -acylation and characterized using different chemical approaches. We validated its binding to the target using in vitro tissue section autoradiography and performed stability tests in vitro and in vivo. [ <superscript>18</superscript> F]FNA- N -CooP was successfully synthesized in 16.8% decay-corrected radiochemical yield with high radiochemical purity (98.5%). It exhibited heterogeneous binding on brain metastasis tissue sections from a patient with breast cancer, with foci of radioactivity binding corresponding to FABP3 positivity. Furthermore, the tracer binding was reduced by 55% in the presence of nonradioactive FNA- N -CooP a blocker, indicating specific tracer binding and that FABP3 is a viable target for [ <superscript>18</superscript> F]FNA- N -CooP. Favorably, the tracer did not bind to necrotic tumor tissue. However, [ <superscript>18</superscript> F]FNA- N -CooP displayed limited stability both in vitro in mouse plasma or human serum and in vivo in mouse, therefore further studies are needed to improve the stability [ <superscript>18</superscript> F]FNA- N -CooP to be used for in vivo applications.

Details

Language :
English
ISSN :
1543-8392
Volume :
21
Issue :
8
Database :
MEDLINE
Journal :
Molecular pharmaceutics
Publication Type :
Academic Journal
Accession number :
39008899
Full Text :
https://doi.org/10.1021/acs.molpharmaceut.4c00546